Postpartum Hypertension Study
Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Whitney A. Booker, MD
- Phone Number: 212-305-7334
- Email: wb2322@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Patients admitted to labor and delivery (L&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg
- Postpartum, immediately to 6 weeks postpartum
- With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy
Exclusion criteria
- They may not have previously had exposure to either study medication within the previous 24-hour period.
- Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Oral Nifedipine
Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of <160 systolic and <105 diastolic is achieved.
If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
|
Oral nifedipine, a short acting ant-hypertensive
Other Names:
|
|
Active Comparator: Intravenous labetalol
Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses.
If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
|
Intravenous labetalol, a short acting ant-hypertensive
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Initial Blood Pressure Control (Minutes)
Time Frame: Up to 48 hours
|
The primary outcome will be time (minutes) interval required to achieve the therapeutic BP goal of <160 mmHg systolic and <110 mmHg diastolic.
|
Up to 48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Number of Participants Who Need for Second Antihypertensive Agent
Time Frame: Up to 48 hours
|
The need to use a second (alternative) antihypertensive medication.
|
Up to 48 hours
|
|
Number of Recurrence of Severe Blood Pressure
Time Frame: Up to 48 hours
|
The number of times a patient has recurrence of severe hypertensive necessitating treatment with an antihypertensive.
|
Up to 48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Whitney A. Booker, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Hypertensive Crisis
- Pre-Eclampsia
- Hypertension
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Amides
- Amines
- Alcohols
- Amino Alcohols
- Ethanolamines
- Dihydropyridines
- Salicylamides
- Nifedipine
- Labetalol
Other Study ID Numbers
Other Study ID Numbers
- AAAT5925
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.